VFMCRP and Fresenius

  • Veltassa® is a      well-tolerated1      and effective2 oral      calcium potassium binder for the treatment of hyperkalemia supported by 12      month clinical data

  • Veltassa® will      benefit from Fresenius Kabi’s market-leading nephrology patient access in      China alongside Velphoro®      and Venofer®

  • China shows high      prevalence of Chronic Kidney Disease (CKD) and heart failure3 

ST GALLEN, Switzerland & BAD HOMBURG, Germany -- (BUSINESS WIRE) --

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005914/en/

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Fresenius Kabi today announced an agreement to develop, register and distribute Veltassa® for the treatment of hyperkalemia in the People’s Republic of China. Under the agreement, Fresenius Kabi will have the exclusive right to distribute and sell Veltassa® across China.

Stefan Schulze, CEO of Vifor Pharma Group comments, “We are delighted to expand VFMCRP’s collaboration with Fresenius Kabi. There is a high prevalence of CKD and heart failure in China3 and hyperkalemia is one of the most common complications associated with these two conditions. As a result there is a high demand for an effective, proven hyperkalemia treatment. The excellent commercial infrastructure, the well established relationships in nephrology and our existing successful collaboration make Fresenius Kabi our partner of choice to provide Veltassa® to patients.”

Oskar Haszonits, President Region Asia Pacific of Fresenius Kabi said, “This agreement is an important step in intensifying our collaboration and relationship with VFMCRP in nephrology. We believe Veltassa® has the potential to provide many benefits to patients across the country, and we look forward to adding it to our portfolio and working with VFMCRP.”

Hyperkalemia is a serious medical condition characterized by elevated levels of potassium in the blood and can be associated with life-threatening consequences. Patients with CKD and heart failure, especially those treated with RAAS (renin-angiotensin-aldosterone system) inhibitors are at particular risk of developing hyperkalemia. As a consequence, RAASi therapy, the cornerstone of treatment for CKD and heart failure, is often reduced or discontinued, compromising cardio-renal protection. By bringing Veltassa® to China, VFMCRP and Fresenius Kabi will deliver a treatment that will enable patients to remain on RAASi therapy by managing their chronic hyperkalemia.

Fresenius Kabi is a global healthcare company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. In China, the company is among the top 10 multinational pharmaceutical companies, being a market leader in clinical nutrition, anesthesia and nephrology. Fresenius Kabi has around 6,000 employees in China.

Both parties have agreed to not disclose financial terms of the collaboration.

Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.

With its corporate philosophy of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.
For more information, please visit www.fresenius-kabi.com.

About Hyperkalemia
Approximately 73% of advanced Chronic Kidney Disease (CKD) and 40% of chronic heart failure patients may be at risk of elevated blood potassium levels4. Hyperkalemia can cause abnormal heart rhythms and even sudden death5. There are often no warning signs, meaning a person can unknowingly experience spikes in potassium levels recurrently and be at risk for these cardiac events. Some medicines that are often prescribed to people with CKD and heart failure to help delay progression of their underlying disease and reduce mortality can cause hyperkalemia as a side effect. These may include RAASi such as angiotensin receptor blockers (ARBs), aldosterone antagonists (AAs) and angiotensin converting-enzyme (ACE) inhibitors as well as angiotensin II receptor/neprilysin inhibitors (ARNI).

About Veltassa®
Veltassa® is a potassium binder approved for the treatment of hyperkalemia. Veltassa® was specially designed to exchange calcium rather than sodium for potassium ions, ensuring suitability for patients who cannot tolerate even small increases in sodium.Veltassa® should not replace emergency treatment for life-threatening hyperkalemia. Made in powder form, Veltassa® is mixed with water and taken once a day with or without food. Veltassa® is consisting of smooth, spherical, uniform microbeads too large to be absorbed, thus protecting the gastrointestinal tract. Veltassa® works primarily in the lumen of the colon where potassium concentration is highest, and the residence time of the polymer is the longest. The potassium is then excreted from the body through the normal excretion process.


1 Veltassa® EU SmPC 2019
2 Agarwal R, et al. Lancet 2019;394:1540–50.
3 Zhang et al. Lancet. 2012 Mar 3;379(9818):815-22; Guo et al. Int J Environ Res Public Health 2016; 13: E770. Guo et al. Curr Cardiol Rev. 2013 May; 9(2): 112–122.
4 Rosano GCM, et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J 2018;4:180-188.
5 Rastegar A, Soleimani M. Hypokalaemia and hyperkalaemia. Postgrad Med J. 2001;77:759-764.


相关推荐
新闻聚焦
猜你喜欢
热门推荐
  • 一只船教育最新消息让人兴奋,退费工作

      在我29岁的时候,我们发了产生报考消防工程师的想法,可能是当时的生活过得很艰辛,而在工作方面一直等不到领导的赏识......

    02-27    来源:阿里教育网

    分享
  • BOP 天堂鸟与大家逆境中冒险

      刚推出新歌《冒险岛》BOP天堂鸟早前于屯门一个篮球场及荃湾一个工作室拍摄MV,面对现时疫情问题他们表示担心,希望新歌......

    04-02    来源:文旅新闻网

    分享
  • 新沐教育最新消息:响应最新政策号召,

      今年毕业了,想考个教资,但是不知道怎么报名,自己也不会教资复习,所以想报个辅导机构来辅助我学习。通过同学的介绍......

    02-27    来源:网络

    分享
  • 践行新型智库建设精神 创建中国创新策划

      本网讯(通讯员 周乐玲) 2019年11月23日,在中国创意策划年会上,由《中国企业报》集团打造的中国策划行业的学术智库机构中国......

    02-02    来源:中华企业在线

    分享
  • 言成教育最新消息,平台为了保证退费工

      当今社会健康管理师可是一个非常热门的职业,有很多青年人都会趁自己有空闲的时间选择报考健康管理师的培训课程增加个......

    02-27    来源:阿里教育网

    分享
  • 学慧网最新消息:想办理退费,请一定要

      如今学慧网已经倒闭跑路了,所以在他家还有剩余学费的小伙伴们,一定要按照我所说的去办退费。 我在2022年7月份在京东上......

    02-27    来源:阿里教育网

    分享
  • 学霸君最新消息 2023年平台计划完成所有

      我家孩子在上高二时就受到了疫情的破坏,因为疫情到大力影响,学生只能在家上网课,可是通过一段时间在家的学习,孩子......

    02-27    来源:阿里教育网

    分享
  • 逸成教育最新消息:现在学费退费了,学

      逸成教育在互联网之上一直在说着,能够帮助我做好学历提升,可是当时我明确表示了自己没有那么多钱去学习,他们就开始......

    02-28    来源:阿里教育网

    分享
  • 兴为教育发布了退费的最新消息,学员们

      作为一个中年男人,平时的收入还没有一个保安的高,虽然我每天都很忙碌,但是也不知道具体忙的什么,钱也没有挣到,家......

    02-27    来源:阿里教育网

    分享
  • 学璐教育新一轮退费公告来了,退费工作

      我是一名全职宝妈,平时把所有的精力全部放在了孩子的身上,但是两个孩子的学习成绩都不怎么样,这让我非常失望,认为......

    02-27    来源:阿里教育网

    分享
返回列表
Ctrl+D 将本页面保存为书签,全面了解最新资讯,方便快捷。